Cybin Company Presentation

Company Highlights (1) https://www.psychedelicscience.ca/publications (2) Forward-looking statements are subject to various risks and assumptions. See “Cautionary Statement Regarding Forward-Looking Information” on page 2 of this presentation. (3) Subject to receipt of all necessary regulatory approvals in Jamaica Management and advisory team has vast experience within the psychedelic, pharmaceutical and nutraceutical sectors and is responsible for some of the first published research on microdosing. (1) IP strategy covering chemically synthesized compounds, delivery mechanisms, screeners & protocols and new drug formulations. As a mushroom driven life sciences company , there is a near term revenue model through non-psychedelic medicinal mushroom products and a mid to long term strategic model to monetize psychedelic assets. (1) Medical team has run multiple clinical trials and facilitated over C$1B in pharma sales. Cybin aims to become one of the first life sciences companies to launch a fully approved psilocybin product targeting depression within Jamaica. (2) (3) Strategic shareholder base with long term investment thesis including biotech funds and former heads of top fortune 100 CPG companies. M&A strategy to acquire revenue generating assets in the medicinal mushroom and psychedelic sector. (2) C$10M successfully raised thus far from Seed and Series-A round. Building strategic partnerships in jurisdictions such as Canada, USA, Jamaica and other European regions. (1) 4 P r i v a t e & C o n f i d e n t i a l

RkJQdWJsaXNoZXIy NDMyMDk=